Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?

Barbro Kjellström1,2 · Anthony Lindholm1 · Ellen Ostenfeld1

Published online: 1 September 2020
© The Author(s) 2020

Abstract
Purpose of Review Pulmonary arterial hypertension (PAH) is a progressive disease with high mortality. A greater understanding of the physiology and function of the cardiovascular system in PAH will help improve survival. This review covers the latest advances within cardiovascular magnetic resonance imaging (CMR) regarding diagnosis, evaluation of treatment, and prognostication of patients with PAH.

Recent Findings New CMR measures that have been proven relevant in PAH include measures of ventricular and atrial volumes and function, tissue characterization, pulmonary artery velocities, and arterio-ventricular coupling.

Summary CMR markers carry prognostic information relevant for clinical care such as treatment response and thereby can affect survival. Future research should investigate if CMR, as a non-invasive method, can improve existing measures or even provide new and better measures in the diagnosis, evaluation of treatment, and determination of prognosis of PAH.

Keywords Pulmonary arterial hypertension · Ventricular remodelling · Atrial remodelling · Pulmonary artery · Tissue characterization · Outcome · Risk assessment

Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease with increased vascular resistance and arterial pressure in the pulmonary circulation. Symptoms such as dyspnoea and fatigue are vague, while there can be a long latency and delay to diagnosis [1]. Mortality is high and most commonly related directly or indirectly to right ventricular (RV) function [1]. While echocardiography currently is the first-line modality to assess cardiac function, assessment of RV volumes and function is challenged by the one- and two-dimensional nature of echocardiography [2–5]. With the complexity of the RV structure, cardiovascular magnetic resonance imaging (CMR) plays an important role in the diagnosis and follow-up of patients with PAH [1, 6]. CMR is the gold standard for cardiac volumes, function, blood flow, and mass (Fig. 1), due to its high accuracy and reproducibility. Furthermore, CMR offers tissue characterization of the ventricular myocardium. In the 2015 ESC/ERS guidelines for diagnosis and treatment of pulmonary hypertension, the only imaging-related parameters included in the risk stratification are right atrial area and pericardial effusion with evidence from echocardiography alone (Table 1) [1]. However, several CMR-related parameters are proven relevant for diagnosis, assessment of disease severity, and prognostication. The purpose of this review is to provide an overview of the latest advances within CMR regarding diagnosis, evaluation of treatment, and prognostication of patients with PAH.

Mass, Volumes, and Function
The increased afterload in PAH can lead to a compensatory RV hypertrophy (Fig. 1(A)), increased ventricular mass index (defined as RV mass divided by left ventricular (LV) mass), and increased RV and atrial volumes (Fig. 1(B–D)).
In the table, the column to the right suggests new measures that could be additional, alternative, or a replacement of measures included in the current ESC/ERS risk stratification (middle column). In line with the scope of this paper, focus is put on how non-invasive measures with CMR might add to the risk assessment in PAH. The CMR images illustrate some of the possible variables of right and left heart function and pulmonary arterial measures that could be considered included in guideline-recommended risk stratification. Here illustrated with an example of right ventricular circumferential strain of the free wall (magenta) and septum (yellow) at a midventricular level, left ventricular longitudinal strain in a three-chamber view (each colour represents a segment), and pulmonary artery vortex formation with posterior retrograde flow (red arrows) during systolic forward flow (yellow arrows) (reprinted from [19], with permission from Elsevier)

**WHO World Health Organization, 6MWD 6-min walked distance, NT-proBNP N-terminal pro-brain natriuretic peptide, CMR cardiovascular magnetic resonance imaging, NA not applicable, MPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, PA pulmonary artery, RVEF right ventricular ejection fraction, RVOT right ventricular outflow tract**

**Table 1** Determinant groups and measures for risk assessment and suggestion for possible adjustments to current measures and/or addition of new measures [1, 115–117]

| Determinant Group | Present measures | Possible additional or new measures |
|-------------------|-----------------|-------------------------------------|
| Present measures  |                 |                                     |

**Ventricular Volumes and Ejection Fraction**

Increased RV volume (Fig. 1C) and reduced LV volume, RV ejection fraction (RVEF), and stroke volume (SV) are noted to be prognostic markers for PAH [14]. When used in conjunction with existing risk assessment tools, these CMR markers show increased value over current prognostic methods for risk classification [15, 16••]. After adjusting for age, sex, and body surface area, 11% could be reclassified as having a higher risk and 36% a lower risk of 1-year mortality [16••].

RVEF has been shown to be the strongest predictor of mortality among these variables in patients with pulmonary hypertension [11, 12••]. When including only patients with pulmonary arterial hypertension, RVEF was the only parameter predicting death and the composite of adverse events comprising all-cause and cardiopulmonary mortality, rehospitalization, lung/lung-heart transplant, and clinical worsening [12••]. It is worth noticing that when excluding patients with congenital heart disease from the PAH group, RVEF only predicted adverse events, not mortality [12••]. This is in agreement with three recent studies on patients with non-congenital PAH, in which RVEF was not associated with death or lung transplant [17•, 18, 19].

**Atrial Volumes and Function**

The importance of right atrial volume (Fig. 1D) and function is becoming more clear regarding the prognosis of patients with PAH [9, 17••, 20, 21••, 22, 23]. They have been shown to be associated with clinical worsening [9]. Patients with right atrial maximum volumes > 74 ml/m² doubled their risk for death or lung transplant compared with patients with normal right atrial volumes [17••]. Moreover, reduced left atrial volumes could be indicative of a LV underfilling in PAH [17•] and have been presented as an indicator of poor prognosis [24, 25].

**Regional Function and Strain**

Ejection fraction is a crude measurement and while many patients with PAH have a preserved LVEF, and at times even a preserved RVEF, this should not be mistaken for a normal ventricular function. Regional RV function, such as myocardial strain (a deformation measured as a change in length; ΔL/L), RV fractional area change, and tricuspid annular plane systolic excursion (TAPSE), are regularly assessed in patients with PAH using echocardiography [1, 2]. Novel techniques to characterize regional ventricular function with CMR are emerging [20, 23, 26–31]. However, and of note,
echocardiographic and CMR equivalent measures are not
directly interchangeable [32].

**Myocardial Strain**

It is well documented that RV and atrial strain measured by
CMR are lower in patients with PAH than in controls [20,
26–29]. LV global longitudinal strain is also lower, despite
preserved LVEF (Fig. 1(E, F)) [21••, 27, 29]. Therefore, in
addition of being a diagnostic tool, myocardial strain might
have utility in prognosis and follow-up of treatment re-
response in patients with PAH [20, 21••, 28]. Reduced strain
increases the risk for adverse events such as death, lung
transplant, and functional class deterioration, incurring a
hazard ratio (HR) of 1.06 for LV longitudinal strain, 2.52
for RV longitudinal strain, and even as much as 4.5 for RV
circumferential strain [28]. Importantly, LV and RV longi-
tudinal strain values increased after initiation of PAH-
dedicated treatment [21••]. The improved strain values cor-
relate with improvements in known prognostic markers of
PAH such as 6-min walk test, pro-BNP, and mean pulmo-
nary arterial pressure (MPAP) [21••]. Furthermore, an in-
terventricular dyssynchronous contraction has been docu-
mented with a left-to-right delay assessed by strain in adult
and paediatric patients with PAH [33–36].

As such, strain assessment with CMR is increasingly inter-
esting in the evaluation of patients with PAH. Moreover, it
shows that there are left-sided implications of this otherwise
considered right-sided disease. The implications are important
for understanding the pump physiology and mechanisms of
the disease as well as for finding early signs of treatment
effect.

**Atrio-Ventricular Plane Displacement**

Atrio-ventricular plane displacement (and tricuspid annu-
lar plane systolic excursion), regional contribution to SV,
and RV fractional area change are novel CMR techniques
for evaluating regional cardiac function in PAH [23, 30,
31, 37]. Both tricuspid annular plane systolic excursion and
fraction area change are shown to have a good corre-
lation with invasive measures such as pulmonary vascular
resistance (PVR) index, MPAP, and RV stroke volume
index [18]. In addition, tricuspid annular plane systolic
excursion ≤18 mm, RV fraction shortening ≤16.7%, and
RV fractional area change ≤18.8% are associated with sur-
vival in PAH, with HRs of 4.8, 3.6, and 3.8, respectively.

Right atrio-ventricular plane displacement (Fig. 1(G, H))
has been shown to be lower in patients with pulmonary hy-
pertension compared with controls, while the longitudinal
contribution to RV stroke volume did not differ between the
groups, owing to increased RV diameter and lower SV among
patients [31]. Interestingly, LV atrio-ventricular plane
displacement and longitudinal contribution to LV SV were
both lower in patients with PAH than controls, despite a pre-
served LVEF in both groups [31]. However, the importance of
these regional alterations regarding morbidity and mortality is
unknown.

**Tissue Characterization**

Myocardial tissue characterization in PAH has been suggested
as a prognostic marker using late gadolinium enhancement
(LGE) and T1 values [1] (Fig. 1(I, J)).

**Late Gadolinium Enhancement**

A gadolinium-based contrast is distributed in relation to
the amount of extracellular space. This results in an
increased concentration of gadolinium and consequently
higher signal intensity (hyperenhancement) in myocardial
scar, fibrosis, or infarction compared to viable myo-
cardium. Typically for PAH, hyperenhancement is pre-
sent at the RV insertion (Fig. 1(I)) [8] and associated
with poor clinical status and survival [8, 38–41].
However, if the fibrosis stretches into the interventricu-
lar septum, hyperenhancement appears to have a stron-
ger association with outcome than fibrosis in the RV
insertion alone [38].

The appearance of fibrosis can vary among aetiologies
of PAH. As such, in patients with congenital heart disease
and PAH (e.g. Eisenmenger with right-to-left shunt and
PAH), the fibrosis in the right ventricle and septum does
not fully resemble that of non-congenital PAH, as in idio-
pathic PAH or PAH associated with connective tissue dis-
orders, such as scleroderma [38, 42]. Furthermore, patients
with scleroderma have been shown to have intrinsic myo-
cardial involvement besides PAH-related alterations [29,
43–48]. In addition, localized LV fibrosis and infarctions
have been shown even in cardiac asymptomatic patients
with scleroderma suggesting a more complex fibrosis pat-
tern in this population of PAH [43, 44].

**T1 Mapping**

While localized fibrosis can be detected by LGE, diffuse
pathology such as general myocardial inflammation and diffuse
fibrosis can be assessed using T1 mapping. Furthermore, T1
mapping can be performed both before and after contrast ad-
ministration which enable calculation of extracellular volume
fraction (ECV) in the myocardium (Fig. 1(J)) [43, 49–56]. T1
mapping and ECV for tissue characterization are relatively
new features applied to patients with PAH [57–65] and have
been shown elevated which indicate fibrosis in the RV ins-
erion points [57, 59–61, 63, 66].
It is, however, still unclear how T1 values should be interpreted, as studies are diverging on whether values are higher in patients with PAH compared with controls [57, 61, 63, 67] or not [58–60, 66, 68]. It should be noted that there is a multitude of different sequences for T1 mapping of which some are heart rate dependent [69]. Patients with PAH are prone to having high heart rate. This is a concern, if special measures are not taken in the acquisition of images [69]. Furthermore, as many of the studies comprise diverse groups of patients, pooling the values into a uniform conclusive value could be considered infeasible. As an example, patients
Fig. 1 Cardiovascular magnetic resonance (CMR) images in a patient with idiopathic pulmonary arterial hypertension. (A) Cine image of 4-chamber view in end diastole showing an enlarged right ventricle (RV) and atrium (RA) and a small left ventricle (LV) and atrium (LA). The RV is hypertrophied, and pericardial effusion is present. (B) Cine short axis stack covering the heart from apex to the base is used for the volumetric assessment of ventricle (C) and atria (D). (C) Example of epicardial and endocardial delineations of both ventricles (in white) and (D) endocardial delineations of both atria. (E) RV and LV tracking for strain analysis in 4-chamber view. (F) Time resolved strain analysis curves for RV and LV (here global longitudinal strain (GLS)). (G) Atrio-ventricular plane in end diastole (red line) in 4-chamber view and (H) in end systole (blue line). Atrio-ventricular displacement (AVPD) is measured as the distance moving from base to apex between the red line in end diastole and the blue line in end systole. The longitudinal contribution to stroke volume (SV) is the volume encompassed by the atrio-ventricular plane marked with blue colour in the left ventricle and green colour in the right ventricle. (I) Phase-sensitive inversion recovery late gadolinium image of short-axis view showing RV insertion fibrosis (white arrows) and (J) increased native T1 values in the corresponding areas. (K, L) Anatomical view of the pulmonary artery delineated in white. (M) Phase-contrast imaging of the pulmonary artery delineated in white from which the flow is computed. (N) Time-resolved pulmonary flow curve during one cardiac cycle. Notice the systolic notch (black arrow), which is indicative of increased pulmonary vascular resistance [111, 120, 121]. (N) 3D plot of pulmonary flow marking the velocity of each voxel from late systolic phase. Simultaneously with the systolic forward flow, backward flow (arrows) is present in the posterior part of the pulmonary artery. This patient had the following data: Volumes and function—RV: end-diastolic volume 356 ml, end-systolic volume 284 ml, stroke volume 72 ml, ejection fraction 20%, mass 83 g; RA maximum volume 292 ml, LA maximum volume 117 ml, end-systolic volume 72 ml, stroke volume 45 ml, ejection fraction 39%, mass 88 g; RA maximum volume 292 ml, LA maximum volume 51 ml. Strain and regional function—peak LV GLS −8.5%, peak RV free wall GLS −9.2%, RV atrio-ventricular plane displacement 11.2 mm, RV longitudinal contribution to SV 64%, RV lateral contribution to SV 36%, LV atrio-ventricular plane displacement 7.5 mm, LV longitudinal contribution to SV 53%, LV lateral contribution to SV 43%, septal contribution to SV 5%. Tissue characterization—T1 values 1420 ms (increased) at the RV insertion points and 1030 ms (normal) in the RV and LV. Pulmonary artery—pulmonary net flow 66 ml, peak velocity 52 cm/s, mean velocity 17 cm/s, area 15.03 cm², distensibility 0.13%/mmHg.

with scleroderma, including those cardiac asymptomatic, have been shown to have increased T1 values [44]. However, the distribution can stand in contrast to patients with congenital heart disease with fibrosis in the right ventricle and septum that does not resemble that of non-congenital PAH [42]. The diversity of patients as well as different sequences are drawbacks for finding a generalizable cut-off value for pathology and outcome. Moreover, the low spatial resolution (1.8 mm × 1.8 mm × 8–10 mm) when assessing the relatively thin RV wall (on average 3–5 mm) is a caveat for generating reliable values as the risk of accidentally including blood in the trabeculations or epicardial fat in the assessment is substantial [49, 50, 69]. One should therefore interpret the T1 values of the right ventricle with caution.

Estimates of Mean Pulmonary Pressure and Pulmonary Resistance

Cardiac and pulmonary artery (PA) pressures and resistance are essential parts of both diagnosis and prognosis of PAH (Fig. 1(K–M)) [1]. Current guidelines denote MPAP ≥25 mmHg (> 20 mmHg is borderline pulmonary hypertension), PVR ≥3 WU, and a normal function of the left ventricle (PA wedge pressure (PAWP)) ≤15 mmHg as manifesting the diagnosis [1, 70]. These key measures determine treatment response [1, 70] and are recommended to be obtained from invasive right heart catheterization (RHC) [1]. While RHC incurs a low morbidity and mortality rate, there are still risks of complications during the intervention, and the examination includes radiation exposure [71]. However, non-invasive methods are emerging as promising alternatives [72, 73].

Estimation of Pulmonary Arterial Pressure with CMR

Estimation of MPAP with CMR using ventricular mass index and interventricular septal angle [74], including RV function along with PA size (Fig. 1(K, L)) [75], has been performed in patients with pulmonary hypertension and chronic obstructive pulmonary disease and showed moderate to good correlation with RHC-derived MPAP. While each of these measurements seems plausible, the use of multiple variable calculations for estimations of values introduces possible sources of error, which is why more direct measures are preferable.

RV pressure overload results in an interventricular shift of the septum toward the left ventricle in patients with PAH (Fig. 1(C)) [76–78]. Leftward septal bowing occurs when the RV pressure is ≥5 mmHg higher than LV pressure [79]. This will contribute to an altered filling of the left ventricle—i.e. cause an underfilling and a decreased LV stroke volume [34]. The ventricular septal curvature has been shown to correlate with systolic PA pressure with a premise of the close correlation between RV systolic pressure and systolic PA pressure [79]. Quantification of the septal curvature duration index (defined as the proportion of CMR frames with a septal bow toward the left that was present during one cardiac cycle) has been shown to be associated with worse prognosis if it lasts >2/3 of the cardiac cycle [80]. A more recent, and direct, method for estimating MPAP by CMR assesses the presence and duration of vortical blood flow in the main PA (Table 1) [81**, 82–85]. A vortex is a formation of concentric ring- or spiral-shaped curves [86–89] and is an effect of coexisting forward flow and retrograde flow at the posterior wall during systole in the main PA (Fig. 1(N)) [81**, 82–85]. The premises for estimating MPAP from vortex formation are (1) detection of a vortex (indicating increased
resistance and decreased elastance) and (2) the time it exists in relation to the full cardiac phase (to evaluate the pressure increase). With these prerequisites, vortex duration has been shown to be accurate in the identification of pulmonary hypertension (a vortex duration \( \geq 14.3\% \) of the cardiac cycle resulted in sensitivity of 0.97 and specificity of 0.96 of detecting pulmonary hypertension) [85]. The accuracy of MPAP needs, however, to be verified in larger, prospective studies from other groups. Furthermore, investigation of the possible effects of pulse wave reflection and PA trunk width would, in the context of vortex formation in the PA, be of interest.

**Estimation of Pulmonary Vascular Resistance and Stiffness with CMR**

PVR, assessed by RHC, is calculated as a ratio of the mean pressure gradient and blood flow in the PA [1]. Non-invasive PVR has been suggested using CMR PA flow metrics (Fig. 1(M, N)) (average and peak velocities) [90–94]. In a meta-analysis, a multitude of different methods (some a combination of PA and RV variables) were compiled and showed a high correlation with PVR from RHC (pooled \( r = 0.81 \) (95% CI 0.74, 0.87)) [95]. Combining RV measures with PA flow metrics (Fig. 1(M)) adds important components in cases with advanced stages of PAH and high PVR, when the PA does not distend further. Hence, the average PA velocity in this late state will only reduce slightly, while RVEF will be more affected [92].

PA stiffness occurs before severe symptoms develop and is an early manifestation of PA remodelling [96–99]. Thus, direct measurements of the stiffness might add accuracy and value to the diagnosis and prognosis of PAH [96, 97]. PA distensibility is one of several measures of PA stiffness and reflects the degree of vascular remodelling as the percent increase in pulmonary vessel diameter in relation to the increase in pressure [74, 96, 100]. It is a strong prognostic marker [74] and has been associated with RV pulmonary arterial uncoupling in patients with unexplained exercise intolerance and normal resting echocardiography results [101].

A novel measure reflecting PA stiffness is PA velocity transfer function, which describes the influence of vessel geometry and compliance/stiffness causing frequency-dependent changes in the input velocity profile (in the proximal part of the PA) as it travels through the artery and thus produces an output velocity profile (in the distal part of the PA) [102]. PA velocity transfer function is strongly associated with invasive measures of PA impedance, stiffness, and vascular resistance. Furthermore, changes in PA velocity transfer function have been shown to be independent of elevation in PAWP. This could be perceived as an advantage in the aging PAH population, as PAWP is affected by age and comorbidities [103]. However, it is yet unknown if alterations in PA velocity transfer function are related to morbidity and outcome.

**Arterial-Ventricular Coupling**

RV failure occurs when the right ventricle can no longer adapt to the elevated pulmonary vascular load. RV pulmonary arterial coupling refers to the energy transfer between ventricular contractility and arterial afterload. It reflects the load imposed upon the right ventricle, as a measure of the right ventricle compensation to the increasing PA stiffness [104–107]. Ventricular contractility is a load-independent measure of systolic function and can be expressed as end-systolic elastance (Ees) [108, 109, 110]. Arterial afterload is the net vascular stiffness and can be expressed as arterial elastance (Ea) [108]. RV pulmonary arterial coupling, measured as Ees/Ea (end-systolic elastance/arterial elastance), has been presented as being useful for prognostication in PAH [111]—to detect pending RV failure [112] in patients with preserved RVEF [109], for example.

Simultaneous information on both function and loading conditions can be interpreted from RV pressure-volume loops. These are in general generated from invasive measures from RHC and volumes. Computation of RV pressure-volume loops could, besides assessing Ees, Ea, and Ees/Ea, be of interest in the investigation of stroke work, potential energy, and ventricular efficiency [107]. A non-invasive computation of pressure-volume loops has been shown to be applicable on the left side using a time-varying elastance model, CMR, and brachial pressure [113]. However, calculating potential energy and mechanical efficiency on the right side requires RV pressure values and an estimation of the RV volume at zero pressure, the \( V_0 \). Both linear regression models [106, 107] and a fixed value [104, 105] have been used to determine \( V_0 \), and future studies are needed for a fully non-invasive computation of RV stroke work and ventricular efficiency as applicable in pulmonary hypertension.

**Outcome and Risk Assessment**

Risk stratification to predict outcome in PAH is vital in the individualization of treatment strategies and improvement of survival (Table 1). Several tools, of different complexity, have been developed [114–118]. To be accepted in daily practice, the tool needs to be clinically applicable and simple to use. On the other hand, PAH is a complex disease and requires advanced investigation to detect disease progression [1] and thus, for a risk assessment tool to be useful, oversimplifying could be a mistake.
Right atrial measures, such as pressure, volume, or area, are not part of the diagnosis, but are important prognostic parameters that can be obtained with RHC, echocardiography, or CMR [1, 2, 119, 120]. It should be noted that in the ESC/ERS risk stratification, the only imaging variables currently included are the right atrial area and pericardial effusion and no RHC measure [1]. In the REVEAL risk score, pericardial effusion is the only imaging-related parameter, while RHC measures of MPAP and PVR are also included [114].

Despite improved treatments and treatment strategies, survival for patients with PAH is still poor. At the first 1-year follow-up after diagnosis, only 17–29% of patients were in a low risk according to the ESC/ERS risk stratification tool [115–117]. There are several ways to construe this information, but two plausible interpretations are that either treatment is not effective enough yet or that other variables need to be assessed for a better prediction—or a combination of these.

Conclusion

Pulmonary arterial hypertension is a progressive disease with high mortality. Haemodynamic measurements, utilizing right heart catheterization, are the gold standard for diagnosis in PAH and to some extent for prognosis. To date, substantial effort is put into mimicking these measures using non-invasive methods like echocardiography and CMR. However, several CMR markers carry prognostic information in themselves and incur a better survival when improved. It is thus warranted that future research investigates these non-invasive methods to see if they can improve existing measures or even provide new and better measures in the diagnosis, evaluation of treatment effect, and determination of prognosis of PAH.

Funding Information Open access funding provided by Lund University.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
• Of major importance

1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.

2. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2018;5(3):G11–24.

3. Lang RM, Bieng M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.

4. Ostenfeld E, Flachskampf FA. Assessment of right ventricular volumes and ejection fraction by echocardiography: from geometric approximations to realistic shapes. Echo Res Pract. 2015;2(1):R1–R11.

5. Rudski LG, Lai WW, Afifalo J, Hua L, Handschuhamacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713 quiz 86–8.

6. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;52(21):1683–92.

7. Jensen AS, Broberg CS, Rydman R, Diller GP, Li W, Dimopoulos K, et al. Impaired right, left, or biventricular function and resting oxygen saturation are associated with mortality in Eisenmenger syndrome: a clinical and cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015;8(12):e003596.

8. Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14:11.

9. Sato T, Tsubo Y, Ohira H, Oyama-Manabe N, Ito YM, Yamada A, et al. Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. J Heart Lung Transplant. 2015;34(3):414–23.
10. Yamada Y, Okuda S, Kataoka M, Tanimoto A, Tamura Y, Abe T, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. Circ J. 2012;76(7):1737–43.

11. Baggen VJ, Leiner T, Post MC, van Dijk AP, Roos-Hesselink JW, Boersma E, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Radiol. 2016;26(11):3771–80.

12. Dong Y, Pan Z, Wang D, Lv J, Fang J, Xu R, et al. Prognostic value of cardiac magnetic resonance-derived right ventricular remodeling parameters in pulmonary hypertension: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2020;13(7):e00568. A systematic review of right ventricular remodelling and outcome that put the pathophysiology in the context of different etiologies.

13. Grapsa J, Tan TC, Nunes MCP, O’Regan DP, Durighel G, Howard L, et al. Prognostic impact of right ventricular mass change in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2020;304:172–4.

14. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250–7.

15. Benza RL, Gomberg-Maitland M, Elliott CG, Garber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–37.

16. Lewis RA, Johns CS, Cogliano M, Capener D, Tuhman E, Elliot CA, et al. Identification of cardiac magnetic resonance imaging thresholds for risk stratification in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2020;201(4):458–68

17. Bredfelt A, Radegran G, Hesselstrand R, Arheden H, Ostenfeld E. Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension. ESC Heart Fail. 2018;5(5):864–75

18. Corona-Villalobos CP, Kamel IR, Rastegar N, Damico R, Kolb TM, Boyce DM, et al. Bidimensional measurements of right ventricular function for prediction of survival in patients with pulmonary hypertension: comparison of reproducibility and time of analysis with volumetric cardiac magnetic resonance imaging analysis. Pulm Circ. 2015;5(3):527–37.

19. Hedstrom E, Bredfelt A, Radegran G, Arheden H, Ostenfeld E. Risk assessment in PAH using quantitative CMR tricuspid regurgitation: relation to heart catheterization. ESC Heart Fail. 2020;7:1653–63.

20. Leng S, Dong Y, Wu Y, Zhao X, Ruan W, Zhang G, et al. Impaired cardiovascular magnetic resonance-derived right semiautomated right atrial longitudinal strain is associated with decompensated hemodynamics in pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2019;12(5):e008582.

21. Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fuji T, et al. The impact of ambisensit and tadalfil upfront combination therapy on cardiac function in sclerodema associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. Pulm Circ. 2018;8(1):2045893217748307

22. Grapsa J, Gibbs JS, Cabrita IZ, Watson GF, Pavlopoulos H, Dawson D, et al. The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging. 2012;13(8):666–72.

23. Seemann F, Baldassarre LA, Llanos-Checa F, Gonzales RA, Grunseich K, Hu C, et al. Assessment of diastolic function and atrial remodeling by MRI—validation and correlation with echocardiography and filling pressure. Physiol Rep. 2018;6(17):e13828.

24. Marston NA, Auger WR, Madani MM, Kimura BJ, Strachan GM, Raisinghani AB, et al. Assessment of left atrial volume before and after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Cardiovasc Ultrasound. 2014;12:32.

25. Motoji Y, Tanaka H, Fukuda Y, Sano H, Ryo K, Imanishi J, et al. Interdependence of right ventricular systolic function and left ventricular filling and its association with outcome for patients with pulmonary hypertension. Int J Cardiovasc Imaging. 2015;31(4):691–8.

26. Zou H, Leng S, Xi C, Zhao X, Koh AS, Gao F, et al. Three-dimensional biventricular strains in pulmonary arterial hypertension patients using hyperelastic warping. Comput Methods Prog Biomed. 2020;189:105345.

27. Kallianos K, Brooks GC, Mukai K, Seguro de Carvalho F, Liu J, Naeger DM, et al. Cardiac magnetic resonance evaluation of left ventricular myocardial strain in pulmonary hypertension. Acad Radiol. 2018;25(1):129–35.

28. de Siqueira ME, Pozo E, Fernandes VR, Sengupta PP, Modesto K, Gupta SS, et al. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2016;18(1):39.

29. Lindholm A, Hesselstrand R, Radegran G, Arheden H, Ostenfeld E. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se. Clin Physiol Funct Imaging. 2019;39(3):215–25.

30. Seemann F, Pahlm U, Steding-Ehrenborg K, Ostenfeld E, Erlinge D, Dubois-Rande JL, et al. Time-resolved tracking of the atrioventricular plane displacement in cardiovascular magnetic resonance (CMR) images. BMC Med Imaging. 2017;17(1):19.

31. Ostenfeld E, Stephensen SS, Steding-Ehrenborg K, Heiberg E, Arheden H, Radegran G, et al. Regional contribution to ventricular stroke volume is affected on the left side, but not on the right in patients with pulmonary hypertension. Int J Cardiovasc Imaging. 2016;32:1243–53.

32. Evaldsson AW, Lindholm A, Jumatare R, Ingvason A, Smith GJ, Waktare J, et al. Right ventricular function parameters in pulmonary hypertension: echocardiography vs. cardiac magnetic resonance. BMC Cardiovasc Disord. 2020;20(1):259.

33. Frank BS, Schafer M, Douwes JM, Ivy DD, Abman SH, Davidson JA, et al. Novel measures of left ventricular electromechanical discoordination predict clinical outcomes in children with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2020;318(2):H401–H12.

34. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJ, et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol. 2008;51(7):750–7.

35. Marcus JT, Mauritz GJ, Kind T, Vonk-Noordegraaf A, Interventricular mechanical dysynchrony in pulmonary arterial hypertension: early or delayed strain in the right ventricular free wall? Am J Cardiol. 2009;103(6):894–5.

36. Schafer M, Collins KK, Browne LP, Ivy DD, Abman S, Friesen R, et al. Effect of electrical dyssynchrony on left and right ventricular
mechanics in children with pulmonary arterial hypertension. J Heart Lung Transplant. 2018;37(7):870–8.

37. Hoette S, Creuze N, Gunther S, Montani D, Savale L, Jais X, et al. RV fractional area change and TAPSE as predictors of severe right ventricular dysfunction in pulmonary hypertension: a CMR study. Lung. 2018;196(2):157–64.

38. Blyth KG, Groenning BA, Martin TN, Foster JE, Mark PB, Dargie HJ, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26(19):1993–9.

39. McCann GP, Beek AM, Vonk-Noordegraaf A, van Rossum AC. Delayed contrast-enhanced magnetic resonance imaging in pulmonary arterial hypertension. Circulation. 2005;112(16):e268.

40. Sanz J, Dellegrottaglie S, Karisa M, Sulica R, Poon M, O'Donnell TP, et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol. 2007;100(4):731–5.

41. Swift AJ, Rajaram S, Capener D, Elliot C, Condiffe R, Wild JM, et al. LGE patterns in pulmonary hypertension do not impact overall mortality. JACC Cardiovasc Imaging. 2014;7(12):1209–17.

42. Broberg CS, Prasad SK, Carr C, Babu-Narayan SV, Dimopoulos K, Gatzoulis MA. Myocardial fibrosis in Eisenmenger syndrome: a descriptive cohort study exploring associations of late gadolinium enhancement with clinical status and survival. J Cardiovasc Magn Reson. 2014;16:32.

43. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson. 2014;16:21.

44. Bratis K, Lindholm A, Hesselstrand R, Arheden H, Karabela G, Stavropoulos E, et al. CMR feature tracking in cardiac asymptomatic systemic sclerosis: clinical implications. PLoS One. 2019;14(8):e202120.

45. Mavrogeni SI, Bratis K, Karabela G, Spiliotis G, Wijk K, Hautemann D, et al. Cardiovascular magnetic resonance imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflamm Allergy Drug Targets. 2015;14(1):29–36.

46. Hromadka M, Seidlerova J, Suchy D, Rajdl D, Lhotsky J, Ludvik J, et al. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients—relationship with biochemical and echocardiography parameters. Int J Cardiol. 2017;249:448–53.

47. Kanski M, Arheden H, Wuttge DM, Bozovic G, Hesselstrand R, Ugander M. Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals—a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes. J Cardiovasc Magn Reson. 2013;15:86.

48. Kobayashi H, Yokoe I, Hirano M, Nakamura T, Nakajima Y, Fontaine KR, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009;36(1):106–12.

49. Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Dreyer KM, et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson. 2012;14:64.

50. Kellman P, Wilson JR, Xue H, Ugander M, Arias AE. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14:63.

51. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.

52. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Correction to: clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2018;20(1):9.

53. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33(10):1268–78.

54. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Choudhary Perzial J, Workman V, Chen X, Chow K, et al. Detection of elevated right ventricular extracellular volume in pulmonary hypertension using Accelerated and Navigator-Gated Look-Locker Imaging for Cardiac T1 Estimation (ANGIE) cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015;17:110.

55. Homsi R, Luetkens JA, Skowasch D, Pizarro C, Sprinkart AM, Gieseke J, et al. Left ventricular myocardial fibrosis, atrophy, and impaired contractility in patients with pulmonary arterial hypertension and a preserved left ventricular function: a cardiac magnetic resonance study. J Thoracic Imaging. 2017;32(1):36–42.

56. Mehta BB, Aupper DA, Guzelsel M, Workman V, Chen X, Chow K, et al. Detection of elevated right ventricular extracellular volume in pulmonary hypertension using Accelerated and Navigator-Gated Look-Locker Imaging for Cardiac T1 Estimation (ANGIE) cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015;17:110.

57. Roller FC, Wiedenroth C, Breithecker A, Liebetrau C, Mayer E, Schneider C, et al. Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2017;27(5):1980–91.

58. Spruijt OA, Vissers L, Bogaard HJ, Hofman MB, Vonk-Noordegraaf A, Marcus JT. Increased native T1-values at the interventricular insertion regions in precapillary pulmonary hypertension. Int J Cardiovasc Imaging. 2016;32(3):451–9.

59. Chen YY, Yun H, Jin H, Kong H, Long YL, Fu CX, et al. Association of native T1 times with biventricular function and hemodynamics in precapillary pulmonary hypertension. Int J Cardiovasc Imaging. 2017;33(8):1179–89.

60. Reiter U, Reiter G, Kovaes G, Adelsmayer G, Greiser A, Olschewski H, et al. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics. Eur Radiol. 2017;27(1):157–66.

61. Saunders LC, Johns CS, Stewart NJ, Oram CJE, Capener DA, Puntnmann VO, et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018;20(1):78.
hypertension: a cardiac magnetic resonance imaging study. Am J Respir Crit Care Med. 2019;200(6):766–9.

65. Nitsche C, Kammerlander AA, Binder C, Duca F, Aschauer S, Koschatnik M, et al. Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging. 2020;21(6):683–91.

66. Wang J, Zhao H, Wang Y, Hermann HC, Witschey WRT, Han Y. Native T1 and T2 mapping by cardiovascular magnetic resonance imaging in pressure overloaded left and right heart diseases. J Thorac Dis. 2018;10(5):2968–75.

67. Pagano JJ, Chow K, Khan A, Michelakis E, Paterson I, Oudit GY, et al. Reduced right ventricular native myocardial T1 in Anderson-Fabry disease: comparison to pulmonary hypertension and healthy controls. PLoS One. 2016;11(6):e0157565.

68. Patel RB, Li E, Benefield BC, Swat SA, Polinelli VB, Carr JC, et al. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail. 2020;7(1):253–63.

69. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson. 2014;16:2.

70. Simonneau G, Montani D, Celermagor DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.

71. Hoojer MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546–52.

72. Johns CS, Kiely DG, Rajaram S, Hill C, Thomas S, Karunasagar K, et al. Diagnosis of pulmonary hypertension with cardiac MRI: derivation and validation of regression models. Radiology. 2019;290(1):61–8.

73. Meyer GMB, Spilimbergo FB, Altmayer S, Pacini GS, Zanon M, Watte G, et al. Multiparametric magnetic resonance imaging in the assessment of pulmonary hypertension: initial experience of a one-stop study. Lung. 2018;196(2):165–71.

74. Swift AJ, Rajaram S, Hurndam J, Hill C, Davies C, Sproston TW, et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imaging. 2013;6(10):1036–47.

75. Moral S, Fernandez-Friera L, Stevens G, Guzman G, Garcia-Alvarez A, Nair A, et al. New index alpha improves detection of pulmonary magnetic resonance indices. Int J Cardiol. 2012;161(1):25–30.

76. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005;16(1):13–8.

77. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hennes AR, Hopkins SR, et al. Pathophysiologic of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53(1):1801900.

78. Klima UP, Lee MY, Guerrero JL, Laraia PJ, Levine RA, Vlahakes GJ. Determinants of maximal right ventricular function: role of septal shift. J Thorac Cardiovasc Surg. 2002;123(1):72–80.

79. Roeleveld RJ, Marcus JT, Faes TJ, Gan TJ, Boonstra A, Postmus PE, et al. Interventricular septal configuration at MR imaging and pulmonary arterial pressure in pulmonary hypertension. Radiology. 2005;234(3):710–7.

80. Mouratoglou SA, Kalifatidis A, Pitsiou G, Grosmanidis V, Kamperidis V, Chalkias G, et al. Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precipillary pulmonary hypertension: a cardiac magnetic resonance study. Hell J Cardiol. 2018;30:S1109-9666(18)30367-1.

81. •• Ramos JG, Fyrdahl A, Wieslander B, Reiter G, Reiter U, Jin N, et al. Cardiovascular magnetic resonance 4D flow analysis has a higher diagnostic yield than Doppler echocardiography for detecting increased pulmonary artery pressure. BMC Med Imaging. 2020;20(1):28 Detailed description and test of a non-invasive method to estimate mean pulmonary pressure. An important step towards a non-invasive diagnosis of PH with high accuracy.

82. Reiter U, Reiter G, Kovacs G, Stalder AF, Gulsun MA, Greiser A, et al. Evaluation of elevated mean pulmonary arterial pressure based on magnetic resonance 4D velocity mapping: comparison of visualization techniques. PLoS One. 2013;8(12):e82212.

83. Reiter G, Reiter U, Kovacs G, Adelsmayr G, Greiser A, Stalder AF, et al. Counter-clockwise vortical blood flow in the main pulmonary artery by 4D flow MRI and Lagrangian ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report. BMC Med Imaging. 2016;16(1):45.

84. Reiter G, Reiter U, Kovacs G, Kainz B, Schmidt K, Maier R, et al. Magnetic resonance-derived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure. Circ Cardiovasc Imaging. 2008;1(1):23–30.

85. Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsberger M. Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. Radiology. 2015;275(1):71–9.

86. Elbaz MS, Calkoen EE, Westenberg JJ, Lieveeldt BP, Roest AA, van der Geest RJ. Vortex flow during early and late left ventricular filling in normal subjects: quantitative characterization using retrospectively-gated 4D flow cardiovascular magnetic resonance and three-dimensional vortex core analysis. J Cardiovasc Magn Reson. 2014;16:78.

87. Toger J, Kanski M, Carlsson M, Kovacs SJ, Soderling L, Arheden H, et al. Vortex ring formation in the left ventricle of the heart: clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801900.

88. Arvidsson PM, Kovacs SJ, Toger J, Borgquist R, Heiberg E, Carlsson M, et al. Vortex ring behavior provides the epigenetic blueprint for the human heart. Sci Rep. 2016;6:22021.

89. Toger J, Kanski M, Arvidsson PM, Carlsson M, Kovacs SJ, Borgquist R, et al. Vortex-ring mixing as a measure of diastolic function of the human heart: phantom validation and initial observations in healthy volunteers and patients with heart failure. J Magn Reson Imaging. 2016;43(6):1386–97.

90. Yan C, Xu Z, Jin J, Lv J, Liu Q, Zhou Z, et al. A feasible method for non-invasive measurement of pulmonary vascular resistance in pulmonary arterial hypertension: combined use of transthoracic Doppler-echocardiography and cardiac magnetic resonance. Non-invasive estimation of pulmonary vascular resistance. Int J Cardiol Heart Vasc. 2015;9:22–7.

91. Muthurangu V, Taylor A, Andriatsimiaovana R, Hegde S, Miquel ME, Tulloh R, et al. Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow. Circulation. 2004;110(7):826–34.

92. Garcia-Alvarez A, Fernandez-Friera L, Mirileis JG, Saviot S, Nair A, Kallman J, et al. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. Eur Heart J. 2011;32(19):2438–45.

93. Bane O, Shah SJ, Cuttica MJ, Collins JD, Selvaraj S, Chatterjee RR, et al. A non-invasive assessment of cardiopulmonary hemodynamics with MRI in pulmonary hypertension. Magn Reson Imaging. 2015;33(10):1224–35.

94. Rogers T, Ratnayaka K, Khan JM, Stine A, Schenke WH, Grant LP, et al. CMR fluoroscopy right heart catheterization for cardiac
output and pulmonary vascular resistance: results in 102 patients. J Cardiovasc Magn Reson. 2017;19(1):54.

95. Chen H, Xiang B, Zeng J, Luo H, Yang Q. The feasibility in estimating pulmonary vascular resistance by cardiovascular magnetic resonance in pulmonary hypertension: a systematic review and meta-analysis. Eur J Radiol. 2019;114:137–45.

96. Bogren HG, Klipstein RH, Mohiaddin RH, Firmin DN, Underwood SR, Rees RS, et al. Pulmonary artery distensibility and blood flow patterns: a magnetic resonance study of normal subjects and of patients with pulmonary arterial hypertension. Am Heart J. 1989;118(5 Pt 1):990–9.

97. Sanz J, Karisma M, Delleo-grottaglie S, Prat-Gonzalez S, Garcia MJ, Fuster V, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovascular Imaging. 2009;2(3):286–95.

98. Agoston-Coldea L, Lupu S, Mocan T. Pulmonary artery stiffness by cardiac magnetic resonance imaging predicts major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. Sci Rep. 2018;8(1):14447.

99. Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;196(2):228–39.

100. Malhotra R, Dhakal BP, Eisman AS, Pappagianopoulos PP, Dress A, Weiner RB, et al. Pulmonary vascular distensibility predicts pulmonary hypertension severity, exercise capacity, and survival in heart failure. Circ Heart Fail. Circ Heart Fail. 2016;9(6):10.1161.

101. Singh I, Oliveira RKF, Naeije R, Rahaghi FN, Oldham WM, Sanz J, Garcia-Alvarez A, Fernandez-Friera L, Nair A, Mirelis JG, Hjalmarsson C, Radegran G, Kylhammar D, Rundqvist B, Trip P, Kind T, van de Veerdonk MC, Marcus JT, de Man FS, Dell'Italia LJ, Walsh RA. Application of a time varying elastance in PAH.

102. Chen H, Xiang B, Zeng J, Luo H, Yang Q. The feasibility in assessing RV-PA coupling in PAH.

103. Hs S, Simpson CE, Houston BA, Wand A, Sato T, Kolb TM, et al. Multi-beat right ventricular-arterial coupling predicts clinical worsening in pulmonary arterial hypertension. J Am Heart Assoc. 2020;9(10):e016031 Brings the understanding of the importance of RV-PA coupling in PAH a step further.

104. Inuzuka R, Hs S, Tedford RJ, Senzaki H. Single-beat estimation of right ventricular contractility and its coupling to pulmonary arterial load in patients with pulmonary hypertension. J Am Heart Assoc. 2018;7(10):e007929. Introduces a new method for assessing RV-PA coupling in PAH.

105. Brewis MJ, Bellofiore A, Vanderpool RR, Chesler NC, Johnson MK, Naeije R, et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol. 2016;218:206–11.

106. Telko K, Dalmer A, Axmann J, Vanderpool R, Ghofrani HA, Naeije R, et al. Reserve of right ventricular-arterial coupling in the setting of chronic overload. Circ Heart Fail. 2019;12(1):e005512.

107. Seemann F, Arvidsson P, Nordlund D, Kopic S, Carlsson M, Arheden H, et al. Noninvasive quantification of pressure-volume loops from brachial pressure and cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2019;12(1):e008493.

108. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354–62.

109. Hooper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoef J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740.

110. Hs S, Simpson CE, Houston BA, Wand A, Sato T, Kolb TM, et al. Multi-beat right ventricular-arterial coupling predicts clinical worsening in pulmonary arterial hypertension. J Am Heart Assoc. 2020;9(10):e016031 Brings the understanding of the importance of RV-PA coupling in PAH a step further.

111. Hs S, Simpson CE, Houston BA, Wand A, Sato T, Kolb TM, et al. Multi-beat right ventricular-arterial coupling predicts clinical worsening in pulmonary arterial hypertension. J Am Heart Assoc. 2020;9(10):e016031 Brings the understanding of the importance of RV-PA coupling in PAH a step further.